Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background & Aims: Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with “advanced cirrhosis” because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non‐response in cirrhotic patients undergoing OCA therapy. Methods: Safety and efficacy of treatment were evaluated in a cohort of consecutive PBC cirrhotic patients started with OCA. OCA response was evaluated according to the Poise criteria. Risk factors for hepatic SAEs and non‐response were reported as risk ratios (RR) with 95% confidence intervals (CIs). Results: One hundred PBC cirrhotics were included, 97 Child‐Pugh class A and 3 class B. Thirty‐one had oesophageal varices and 5 had a history of ascites. Thirty‐three per cent and 32% of patients achieved a biochemical response at 6 and 12 months respectively. Male sex (adjusted‐RR 1.75, 95%CI 1.42–2.12), INR (1.37, 1.00–1.87), Child‐Pugh score (1.79, 1.28–2.50), MELD (1.17, 1.04–1.30) and bilirubin (1.83, 1.11–3.01) were independently associated with non‐response to OCA. Twenty‐two patients discontinued OCA within 12 months: 10 for pruritus, 9 for hepatic SAEs (5 for jaundice and/or ascitic decompensation; 4 for upper digestive bleeding). INR (adjusted‐RR 1.91, 95%CI 1.10–3.36), lower albumin levels (0.18, 0.06–0.51), Child‐Pugh score (2.43, 1.50–4.04), history of ascites (3.5, 1.85–6.5) and bilirubin (1.30, 1.05–1.56), were associated with hepatic SAEs. A total bilirubin≥1.4 mg/dl at baseline was the most accurate biochemical predictor of hepatic SAEs under OCA. Conclusions: An accurate baseline assessment is crucial to select cirrhotic patients who can benefit from OCA. Although OCA is effective in one third of cirrhotics, bilirubin level ≥1.4 mg/dl should discourage from its use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480 · cited 2×
“Liver cirrhosis was defined by either: (1) liver histology; and/ or (2) liver stiffness by vibration- controlled transient elastography≥16.”
MethodSelf-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 1×
“Duration of disease before OCA start, years 9 (5, 15) Body Mass Index, Kg/m2 24.”
BackgroundSelf-citationCarbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.005 · Cited by 386 · cited 2×
“Liver cirrhosis was defined by either: (1) liver histology; and/ or (2) liver stiffness by vibration- controlled transient elastography≥16.”
BackgroundMethodSelf-citationVerbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258
Trauner, M., Nevens, F., Shiffman, M. L., Drenth, J. P. H., Bowlus, C. L., Vargas, V., Andreone, P., Hirschfield, G. M., Pencek, R., Malecha, E. S., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30094-9 · Cited by 180
Carbone, M., Nardi, A., Flack, S., Carpino, G., Varvaropoulou, N., Gavrila, C., Spicer, A., Badrock, J., Bernuzzi, F., Cardinale, V., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30163-8 · Cited by 155
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2022) · Hepatology · doi:10.1002/hep.32117 · Cited by 146
Real-world experience with obeticholic acid in patients with primary biliary cholangitis
D’Amato, D., De Vincentis, A., Malinverno, F., Viganò, M., Alvaro, D., Pompili, M., Picciotto, A., Palitti, V. P., Russello, M., Storato, S., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100248 · Cited by 85
Self-citationReal‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
Roberts, S. B., Ismail, M., Kanagalingam, G., Mason, A. L., Swain, M. G., Vincent, C., Yoshida, E. M., Tsien, C., Flemming, J. A., Janssen, H. L. A., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1518 · Cited by 58
John, B. V., Schwartz, K., Levy, C., Dahman, B., Deng, Y., Martin, P., Taddei, T. H., & Kaplan, D. E. (2021) · Hepatology Communications · doi:10.1002/hep4.1720 · Cited by 51
Cited by
Obeticholic Acid for Primary Biliary Cholangitis
Floreani, A., Gabbia, D., & De Martin, S. (2022) · Biomedicines · doi:10.3390/biomedicines10102464 · Cited by 41
“A further analysis was performed in 100 cirrhotic patients of the Italian cohort [45].”
MethodSelf-citationAlkhouri, N., LaCerte, C., Edwards, J., Poordad, F., Lawitz, E., Lee, L., Karan, S., Sawhney, S., Erickson, M., MacConell, L., et al. (2024) · Liver International · doi:10.1111/liv.15816 · Cited by 23
Ampuero, J., Lucena, A., Berenguer, M., Hernández-Guerra, M., Molina, E., Gómez-Camarero, J., Valdivia, C., Gómez, E., Casado, M., Álvarez-Navascuez, C., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000826 · Cited by 17
Advancing care in primary biliary cholangitis: emerging insights and novel therapies
Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516622 · Cited by 5
“As with any therapy, benefit is limited in advanced disease stages, where risk of adverse side increases disproportionately [36–38].”
Metadata
- Authors
- De Vincentis, A., D'Amato, D., Cristoferi, L., Gerussi, A., Malinverno, F., Lleo, A., Colapietro, F., Marra, F., Galli, A., Fiorini, C., Coco, B., Brunetto, M., Niro, G. A., Cotugno, R., Saitta, C., Cozzolongo, R., Losito, F., Giannini, E. G., Labanca, S., Marzioni, M., Marconi, G., Morgando, A., Pellicano, R., Vanni, E., Cazzagon, N., Floreani, A., Chessa, L., Morelli, O., Muratori, L., Pellicelli, A., Pompili, M., Ponziani, F., Tortora, A., Rosina, F., Russello, M., Cannavò, M., Simone, L., Storato, S., Viganò, M., Abenavoli, L., D'Antò, M., De Gasperi, E., Distefano, M., Scifo, G., Zolfino, T., Calvaruso, V., Cuccorese, G., Palitti, V. P., Sacco, R., Bertino, G., Frazzetto, E., Alvaro, D., Mulinacci, G., Palermo, A., Scaravaglio, M., Terracciani, F., Galati, G., Ronca, V., Zuin, M., Claar, E., Izzi, A., Picardi, A., Invernizzi, P., Vespasiani‐Gentilucci, U., Carbone, M., & on behalf of the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group and, T. I. P. R.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2022-08-23
- Volume
- 42
- Issue
- 11
- Pages
- 2453-2465
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W4289929856
- Cited by
- 30
- References
- 11
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid. https://app.cochat.ai/papers/10.1111/liv.15386
- The paper
- De Vincentis, A., D'Amato, D., Cristoferi, L., Gerussi, A., Malinverno, F., Lleo, A., Colapietro, F., Marra, F., Galli, A., Fiorini, C., Coco, B., Brunetto, M., Niro, G. A., Cotugno, R., Saitta, C., Cozzolongo, R., Losito, F., Giannini, E. G., Labanca, S., . . . on behalf of the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group and, T. I. P. R. (2022). Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid. Liver International. https://doi.org/10.1111/liv.15386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.